BofA analyst Craig Bijou downgraded Haemonetics (HAE) to Underperform from Neutral with a price target of $68, down from $95, after Q3 revenue missed and the company lowered FY25 organic growth guidance. The quarter likely adds to investor worries on the plasma market recovery and durability of Vascade growth, notes the analyst, who also expects tariffs to remain “somewhat of an overhang” as Haemonetics has higher exposure to Mexico and Canada.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HAE:
Questions or Comments about the article? Write to editor@tipranks.com